Author

Naoki Haratake

Harvard UniversityORCID 0000-0002-3098-4798Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

Atrayee BhattacharyaiD· 2 shared Donald W. KufeiD· 2 shared Kentaro NonakaiD· 2 shared Mark D. LongiD· 2 shared Shinkichi TakamoriiD· 2 shared Tomoharu YoshizumiiD· 2 shared Tomoyoshi TakenakaiD· 2 shared Aaron N. HataiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Atrayee BhattacharyaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyOncogenePeer-reviewedAug 5, 2026

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors

Shinkichi Takamori, Naoki Haratake, Atrayee Bhattacharya…·Donald W. Kufe

This study identifies M1C as a driver of sotorasib resistance in NSCLC KRAS G12C mutant tumors and shows that targeting M1C improves treatment outcomes.

1 citation

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJun 23, 2026

M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS

Shinkichi Takamori, Naoki Haratake, Kentaro Nonaka…·Donald W. Kufe

This study shows M1C is necessary for daraxonrasib resistance in NSCLC KRAS(G12C) mutant cells and identifies M1C as a potential therapeutic target.

DOI 10.64898/2026.06.20.733526

humanexperimental assay

𝕏 PostBluesky